Sparks - IRLAB Therapeutics

IRLAB Therapeutics has announced top-line results from the Phase IIb REACT-PD study evaluating its second most clinically advanced asset, pirepemat, as a potential treatment for falls related to Parkinson’s disease (PF-Falls), a common comorbidity to the condition. The company has noted that, while the high-dose arm (600mg daily) reported a 42% reduction in falls over the 12-week study duration, the results were not statistically significant over the placebo arm. Moreover, while the high-dose arm indicated a meaningful improvement in cognitive impairment on the Montreal Cognitive Assessment scale, these results were also not statistically significant.

Management will now conduct an in-depth analysis of the study data and, while we await further details of the results, we expect, at the least, a significant impact on the development timelines for the asset. The stock is trading down 51% at the time of writing.